Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 2Phase 1/2 2Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 15INDUSTRY 13NIH 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Pancreatic Neoplasms 14Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13

Interventions

Ipilimumab 2glembatumumab vedotin 1aldesleukin 1Nivolumab 1CTLA-4 Antigen 1CR011-vcMMAE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Uveal Melanoma × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00058279 2013-06-20

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1/2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡